Table 1.
Patients’ characteristics.
| Parameter | n (%) |
|---|---|
| Patient number | 47 |
| Sex | |
| Male | 26 (55.3%) |
| Female | 21 (44.7%) |
| Median Age (range) | 56 (33–74) |
| Age ≥ 60 | 20 (42.5%) |
| Age ≥ 70 | 5 (10%) |
| De novo AML | 40 (85%) |
| Secondary AML | 7 (15%) MDS, n = 4 Therapy-related, n = 3 |
| ELN 2017 risk at diagnosis | |
| Favorable | 16 (34%) |
| Intermediate | 17 (36%) |
| Adverse | 7 (15%) |
| NA | 7 (15%) |
| NPM1/FLT3 status | |
| NPM1mut FLT3-ITDwt | 7 (15%) |
| NPM1mut FLT3-ITDpos | 6 (13%) |
| NPM1neg FLT3-ITDwt | 27 (57%) |
| NPM1neg FLT3-ITDpos | 7 (15%) |
| Cytogenetic risk | |
| Low risk | 5 (11%) |
| Intermediate risk | 31 (66%) |
| Poor risk | 8 (17%) |
| Unknow | 13 (28%) |
| Setting | |
| First relapse | 20 (43%) |
| Subsequent relapse | 5 (11%) |
| Relapse after HSCT | 11 (23%) |
| Partner drug | |
| Azacitidine | 29 (62%) |
| Decitabine | 5 (11%) |
| Low-dose cytarabine | 13 (28%) |
| Median cycle number (range) | 2 (1–24) |
| Intention to treat | |
| Intention to HSCT | 24 (51%) |
| Nointention to HSCT | 23 (49%) |
| HSCT performed | 13/24 (54%) |